Skip to main content
Clinical Trials/NCT01805492
NCT01805492
Completed
Not Applicable

Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal

Windber Research Institute1 site in 1 country422 target enrollmentJanuary 2000

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Diseases
Sponsor
Windber Research Institute
Enrollment
422
Locations
1
Primary Endpoint
Change in body mass index
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The purpose of this study is to characterize changes in gene and protein expression in peripheral blood in patients with, or at risk for, heart disease during an intensive lifestyle modification program.

Detailed Description

This project will use an integrated approach that examines DNA variation and the functional products of genes at both the messenger RNA (mRNA) and protein levels to provide a global view of molecular changes associated with drastic lifestyle modifications designed to reverse coronary heart disease (CHD). DNA variants and/or changes in gene and protein expression associated with CHD reversal may provide important clues to understanding molecular mechanisms of subclinical CHD development and progression.

Registry
clinicaltrials.gov
Start Date
January 2000
End Date
February 2009
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Darrell L Ellsworth

Senior Director, Integrative Cardiac Health Program

Windber Research Institute

Eligibility Criteria

Inclusion Criteria

  • diagnosis of coronary artery disease (CAD)
  • stable angina
  • angioplasty
  • evidence of \>50% luminal narrowing on coronary angiogram
  • acute myocardial infarction
  • bypass surgery
  • stent placement OR
  • two or more CAD risk factors
  • systolic pressure \>140 mm Hg or diastolic pressure \>90 mm Hg)
  • high total cholesterol (\>200 mg/dL)

Exclusion Criteria

  • known history of autoimmune disease
  • systemic/chronic disease requiring chemotherapy or long term treatment

Outcomes

Primary Outcomes

Change in body mass index

Time Frame: Baseline, 12 weeks, 52 weeks

Change in BMI from baseline to 12 weeks and from baseline to 52 weeks

Secondary Outcomes

  • Change in blood pressure(Baseline, 12 weeks, 52 weeks)
  • Change in lipids(Baseline, 12 weeks, 52 weeks)
  • Change in exercise capacity(Baseline, 12 weeks, 52 weeks)

Study Sites (1)

Loading locations...

Similar Trials